期刊文献+

多发性骨髓瘤患者化疗期间感染炎症指标及FcγRIIA基因多态性与预后的关联

Association of infection-induced inflammatory markers and Fc-γRIIA gene polymorphism with prognosis in patients with multiple myeloma during chemotherapy
原文传递
导出
摘要 目的探究多发性骨髓瘤患者化疗期间感染炎症指标及FcγRIIA基因多态性与预后的关联.方法回顾性分析2020年1月-2023年2月山东大学齐鲁医院(青岛)55例多发性骨髓瘤化疗期间感染患者(研究组)与65例多发性骨髓瘤化疗期间未感染患者(对照组)的临床资料,研究组根据预后情况分为预后良好组(29例)和预后不良组(26例);检测患者静脉血中性粒细胞与淋巴细胞比值(NLR)、单核细胞和淋巴细胞比值(MLR)与血小板淋巴细胞比值(PLR)、降钙素原(PCT)、FcγRIIA基因多态性.结果研究组静脉血NLR、MLR、PLR、PCT均高于对照组;预后不良组静脉血NLR、MLR、PLR、血清PCT均高于预后良好组(P<0.05);研究组FcγRIIA-R型占比高于对照组,FcγRIIA-H型占比低于对照组(P<0.05);预后不良组FcγRIIA-R型占比高于预后良好组,FcγRIIA-H型占比低于预后良好组(P<0.05).结论临床多发性骨髓瘤患者化疗期间感染及不良预后与静脉血NLR、MLR、PLR、PCT水平异常升高有关,且FcγRIIA基因多态性与多发性骨髓瘤患者化疗期间感染的发生及不良预后有明显关系. OBJECTIVE To investigate the association of inflammatory index of infection and FCRIIA gene polymorphism with prognosis of multiple myeloma patients during chemotherapy.METHODS Clinical data of 55 patients with multiple myeloma infected during chemotherapy(the study group)and 65 patients without infection during chemotherapy(the control group)admitted to Qilu Hospital of Shandong University(Qingdao)from Jan.2020 to Feb.2023 were retrospectively analyzed,and the patients in the study group were divided into a good prognosis group(29 cases)and a poor prognosis group(26 cases)according to prognosis.The NLR,MLR,PLR,serum PCT and gene polymorphisms of Fc-γRIIA in venous blood were detected.RESULTS The NLR,MLR,PLR,PCT in venous blood of the study group were higher than those of the control group.The NLR,MLR,PLR and serum PCT in venous blood of the poor prognosis group were higher than those of the good prognosis group(P<O.05).The Fc-γRIIA-R type in the study group was higher than that in the control group,while the Fc-γRIIAH type was lower than that in the control group(P<0.05).The percentage of Fc-γRIIA-R type in the poor prog-nosis group was higher than that in the good prognosis group,while the percentage of Fc-γRIIA-H type was lower than that in the good prognosis group(P<0.05).CONCLUSION Infection and poor prognosis of patients with multiple myeloma during chemotherapy were associated with abnormally elevated levels of NLR,MLR,PLR in venous blood and serum PCT,and the polymorphism of Fc-γRIIA gene was significantly associated with infection and poor prognosis of patients with multiple myeloma during chemotherapy.
作者 张玉芬 李旻雪 仲杰 曹乃月 ZHANG Yu-fen;LI Min-xue;ZHONG Jie;CAO Nai-yue(Qilu Hospital of Shandong University(Qingdao),Qingdao,Shandong 266000,China)
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2024年第11期1711-1714,共4页 Chinese Journal of Nosocomiology
基金 山东省自然科学基金青年基金资助项目(ZR2021QH326)。
关键词 多发性骨髓瘤 化疗 感染 致炎指标 FcγRIIA 基因多态性 Multiple myeloma Chemotherapy Infection Inflammatory index FcγRIIA Gene polymorphism
  • 相关文献

参考文献6

二级参考文献62

  • 1中国医师协会,中华医学会血液学分会,中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南(2013年修订)[J].中华血液学杂志.2013,52:791-795.
  • 2NCCN肿瘤学临床指南.多发性骨髓瘤.2014年第2版.1-32.
  • 3Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma:the experience of the Intergroupe Franco- phone du Myelome [ J ]. Blood,2007,109 ( 8 ) : 3489-3495.
  • 4Fonseea R, Bergsagel PL, Draeh J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009,23 (12) :2210-2221.
  • 5Sonneveld P,Schmidt-Wolf IG,van der Holt B ,et al. Bortezomib induc- tion and maintenance treatment in patients with newly diagnosed multi- ple myeloma: results of the randomized phase III HOVON-65/GMMG- HIM trial[J]. J Clin 0ncol,2012,30(24) :2946-2955.
  • 6Gay F,Hayman SR,Lacy MQ,et al. Lenalidomide plus dexamethasone ver- sus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients[J]. Blood,2010,115(7) :1343-1350.
  • 7Gregory WM, Richards MA,Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published triMs[J]. J Clin Onco1,1992,10(2) :334-342.
  • 8Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and predni- sone chemotherapy plus thalidomide compared with melphalan and pred- nisone alone in elderly patients with multiple myeloma:randomised con- trolled trial [ J ]. Lancet,2006,367 ( 9513 ) : 825-831.
  • 9San Miguel JF,Schlag R,Khuageva NK,et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-mel- phalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma[J]. J Clin Oncol,2013,31(4) :448-455.
  • 10Michael M,Bruns I,Bolke E,et al. Bendamustine in patients with relapsed or refractory multiple myeloma[ J]. Eur J Med Res,2010,15( 1 ) :13-19.

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部